Zydus Lifesciences introduced on Wednesday that it had signed an settlement through its subsidiary to acquire Assertio Holdings Inc. for $166.4 million in an all-cash deal. Assertio is a Nasdaq-listed pharmaceutical company centered on specialty and oncology supportive-care therapies.
Underneath the deal, Zydus Worldwide DMCC will acquire all excellent shares of Assertio for $ 23.50 every, representing whole consideration of about $166.4 million on a completely diluted foundation.
The acquisition offers Zydus with a longtime US specialty oncology business platform, anchored by Assertio’s presence in oncology supportive care, the company stated on Wednesday. It plans to leverage Assertio’s business infrastructure and oncology relationships to construct and develop its specialty oncology presence in the US.
Zydus’s supply trumped these of its opponents, rising because the ‘superior proposal’, Assertio stated in an announcement. The deal represents a 30.6% premium to the beforehand introduced $18-per-share all-cash transaction with Garda Therapeutics on 8 April 2026, and a 7.8% premium to the $21.80-per-share all-cash transaction with Garda introduced on 4 Might 2026.
It additionally represents a 75.8% premium to the company’s unaffected closing inventory worth on 20 March 2026, the day earlier than important actions in the share worth and buying and selling volumes. Assertio’s share worth on the Nasdaq as of 11:35 am on 13 Might was $23.31.
Underneath the phrases of the merger settlement, Zydus will start a young supply to acquire all excellent shares of Assertio frequent inventory. The transaction is structured as a young supply, to be adopted by a merger.
The tender supply is anticipated to start inside 5 enterprise days of the merger settlement. The transaction is anticipated to shut this monetary yr, offered all closing situations are met.
“This transaction represents a strategic step in strengthening our specialty and oncology footprint in the US. Assertio brings a centered business platform and an accredited oncology asset that aligns nicely with our long-term technique of constructing differentiated, sturdy specialty companies globally,” Sharvil Patel, managing director of Zydus Lifesciences stated.
Procuring spree
This deal is the newest in a string of abroad acquisitions by the Ahmedabad drugmaker because it appears to be like to diversify and strengthen its specialty performs in regulated markets. In June 2025 it introduced the acquisition of two biologics manufacturing amenities from US-based Agenus Inc. for up to $125 million, serving to it enter the worldwide biologics CDMO market. In July, it agreed to acquire an 85.6% stake in French orthopaedics agency Amplitude Surgical for about €256.8 million, marking its entry into the worldwide medtech house.
Mint reported in January that Zydus was evaluating a majority stake buy in US-based Ardelyx Inc. in a deal valued at $2.2-2.5 billion.
Source link
#Zydus #acquire #cancer #drug #company #Assertio #million #allcash #deal #Company #Business #News
